Status: Ongoing
First registered on:
18/08/2020
Last updated on:
19/08/2020
1. Study identification
EU PAS Register NumberEUPAS36804
Official titleRisk and course of COVID-19 infection in patients with hypo- or hyperthyroidism. A Danish population-based cohort study
Study title acronymThyroid dysfunction and COVID-19 infection
Study typeObservational study
Brief description of the studyBackground: At present there are no data regarding the risk and course of COVID-19 in patients with hypo- or hyperthyroidism. As hypo- and hyperthyroidism are quite common conditions any association with risk and prognosis of COVID-19 may have important public health impact. Thus, there is an urgent need to clarify whether there is an increased risk and/or worsened prognosis of COVID-19 in patients with hypo- or hyperthyroidism, using high quality population-based data.
Objective: To examine the risk and course of COVID-19 in patients with hypo- and hyperthyroidism.
Exposure: Hypo- and hyperthyroidism are defined as use of Levothyroxine and anti-thyroid drugs, respectively.
Outcomes: Primary outcomes are death, hospitalization, intensive care unit admission within 30 days after a positive test for COVID-19. The secondary outcome is risk of COVID-19 in patients with hypo- or hyperthyroidism.
Methods: Nationwide register based study including all persons tested for COVID-19 in Denmark (1.417.864; mid August 2020). The impact of hypo- and hyperthyroidism on risk of acquiring COVID-19 will be examined using a case-control design, while the prognosis will be evaluated in a cohort of COVID-19 positive patients. The odds ratio for hypo- and hyperthyroidism will be estimated using logistic regression models adjusted for age, gender, and comorbidity.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupOdense University Pharrnacoepidemiological Database
Organisation/affiliationUniversity of Southern Denmark
Details of (Primary) lead investigator
Title Professor
Last name Hallas
First name Jesper
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?2
Department of Endocrinology, Odense University hospital, Sdr. boulevard 29, 5000 C Odense, Denamrkl, Denmark
Countries in which this study is being conducted
National study
Denmark
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed27/02/202027/02/2020
Start date of data collection27/02/202027/02/2020
Start date of data analysis01/10/2020
Date of interim report, if expected
Date of final study report16/11/2020
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding scheme
OtherUniversity of Southern Denmark100
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Brix
First name Thomas
Address line 1Department of Endocrinology, Odense University hospital, Sdr. boulevard 29
Address line 2
Address line 3
CityOdense
Postcode5000 C
CountryDenmark
Phone number (incl. country code)45-65411885
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Dr
Last name Brix
First name Thomas
Address line 1Department of Endocrinology, Odense University hospital, Sdr. boulevard 29
Address line 2
Address line 3
CityOdense
Postcode5000 C
CountryDenmark
Phone number (incl. country code)4565411885
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)H03A (Thyroid hormones)
Substance class (ATC Code)H03B (ANTITHYROID PREPARATIONS)
7. Medical conditions to be studied
Medical condition(s)Yes
Hypothyroidism
Hyperthyroidism
COVID-19
8. Population under study
Age
Preterm newborns
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
Other population
Renal impaired
Hepatic impaired
Immunocompromised
Pregnant women
9. Number of subjects
Estimated total number of subjects15000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Administrative database, e.g. claims database
Pharmacy dispensing records
11. Scope of the study
What is the scope of the study?
Risk assessment
Primary scope : Risk assessment
12. Main objective(s)
What is the main objective of the study?
To examine the risk and course of COVID-19 in patients with hypo- and hyperthyroidism
Are there primary outcomes?Yes
30-day mortality after positive RT-PCR for SARS-CoV-2 as identified using the Danish Register of Causes of Deaths.
The risk of COVID-19 in patients with hypo- or hyperthyroidism.
Are there secondary outcomes?Yes
hospitalization, intensive care unit admission within 30 days after a positive test for COVID-19.
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
Patients will be followed from the date of their positive test for SARS-CoV-2 and the following 30 days for all outcomes. However, since many patients with COVID-19 seem to have a prolonged disease course a sensitivity analysis using a follow up of 60 days will be conducted for each outcome variable.
15. Data analysis plan
Please provide a brief summary of the analysis method
Propensity-score weighted risk, risk difference and risk ratio for the outcomes. Adjusted odds ratio for positive test among all tested.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Available when the study ends
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
